On the Use of the Accelerated Failure Time Model As An Alternative to the Proportional Hazards Model in the Treatment of Time to Event Data: A Case Study in Influenza
Tóm tắt
Từ khóa
Tài liệu tham khảo
Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, Singh S, Kinnersley N, Ward P, Mills RG. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA. 2000;283:1016–1024.
Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, Rode A, Kinnersley N, Ward P. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. The Lancet. 2000;355:1845–1850.
Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: Wiley; 1972: 144–147.
Cox DR. Regression models and life-tables (with discussion). J Roy Stat Society, Series B. 1972;34:187–220.
Keiding N, Anderson PK, Klein JP. The role of frailty models and accelerated failure time models in describing heterogeneity due to omitted covariates. Stat Med. 1997;16:215–224.
Hougaard P, Myglegaard P, Borch-Johnsen K. Heterogeneity models of disease susceptibility, with application to diabetic nephropathy. Biometrics. 1994;50: 1178–1188.
SAS Institute Inc. SAS/STAT User’s Guide. Version 6, Fourth Edition, Volume 2. Cary, NC: SAS Institute Inc.; 1989.